Concomitant treatment with glucocorticoids inhibits the growth promoting effect of somatropin. Patients with ACTH deficiency should have their glucocorticoid replacement therapy carefully adjusted to avoid any inhibitory effect on somatropin.
Data from an interaction study performed in growth hormone deficient adults suggest that somatropin administration may increase the clearance of compounds known to be metabolised by cytochrome P450 isoenzymes. The clearance of compounds metabolised by cytochrome P450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine) may be especially increased resulting in lower plasma levels of these compounds. The clinical significance of this is unknown.
In insulin treated patients adjustment of insulin dose may be needed after initiation of somatropin treatment. The effect of growth hormone on final height can also be influenced by additional therapy with other hormones, e.g. gonadotropin, anabolic steroids, estrogens and thyroid hormone.